Wary pharma: AstraZeneca sours on UK

AI is changing how we work. It's turning us all into managers. Be a good one.The Economist’s management columnist, Andrew Palmer, takes on the bots in the third season of Boss Class. From cloning to coding, agents to entry-level jobs, he tackles the threat head on and figures out ...  Show more

The two men under investigation are in the army’s highest echelon, and are some of President Xi Jinping’s closest counsel. We examine the probable motives for a surprising purge. In Ukraine’s freezing capital thousands upon thousands of people suffer unpredictable cuts to electri ...  Show more

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more

Trade ties between <a href="https://www.economist.com/the-americas/2024/11/17/brazil-courts-china-as-its-musk-feud-erupts-again?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term= ...

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Show more

With China as its new rival, America is reviving old wartime facilities across the Pacific. Our correspondent visits an abandoned airfield that has been given new life. The outlook for climate technology is surprisingly bright. And why the universe of Hello Kitty keeps expanding. ...  Show more